Tagged with IOT

Hong Kong At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper, however, and its distinctive and differentiated offering becomes ever more apparent.    “While Hong Kong’s biomedical ecosystem certainly still lags…

Denmark Ian Laquian’s journey from Big Pharma strategy leadership to entrepreneurial venture creation exemplifies the innovative thinking required to address intractable neurological challenges. Having spearheaded CNS therapeutic area strategy at Takeda Pharmaceuticals, Laquian has pioneered a ground-breaking approach that leverages metabolic pathways to treat neurodegenerative diseases. Through the establishment of Kariya…

Denmark As Denmark positions itself as a rising force in global life sciences, the BioInnovation Institute (BII) stands at the centre of this momentum, bridging world-class academic research with entrepreneurial ambition. In this conversation, CEO Jens Nielsen shares how BII is scaling its proven model, shaping Denmark’s innovation environment, and drawing…

Switzerland From regenerating damaged muscles to rewriting the cell manufacturing playbook, Switzerland’s next wave of biotech innovators is turning regenerative medicine into a precision science. Once considered futuristic, technologies like autologous tissue grafts, gene-edited therapies, and cell-state reprogramming are now gaining real-world traction with Swiss startups at the forefront. These five…

Switzerland Luc Henry, co-founder and CEO of Limula, speaks about the challenges and opportunities in the field of cell and gene therapy. A chemist by training, Henry’s path from molecular sciences to cancer immunology and ultimately to entrepreneurship reveals how interdisciplinary thinking can catalyse bold innovation. In this conversation, Henry explains…

Switzerland Thomas Bohn has led the Greater Geneva Bern area (GGBa) investment agency for over a decade, shaping Switzerland’s strategy to attract global life sciences firms. He focuses on quality over quantity, targeting high-potential biotech, pharma, and medtech companies and supporting their European growth through sustainable partnerships. Switzerland’s life sciences heritage…

China Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with the speed of a startup and the reach of an MNC. As Founder, CEO, and Chairman of Duality Biotherapeutics, Zhu…

Switzerland Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from a translational research programme in Switzerland to pioneer a first-in-class therapeutic strategy targeting the endocannabinoid system, a master regulator of…

China Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he took the helm at VISEN Pharmaceuticals. Tasked with shaping the company from its inception, he brought not only decades of…

China 2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic, scientific, and operational advances shaping the company’s trajectory. With its proprietary HCAb platform at the core, Harbour BioMed is extending…

Singapore Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration with global contract research organizations and large vendors during the clinical development phase. Stacey also shares insights into Cerecin’s approach…

Switzerland What if the key to treating chronic and age-related diseases has been hidden in plain sight, within the 98 percent of the human genome once written off as “junk”? HAYA Therapeutics is betting on it. In this interview, CEO and Scientific Co-Founder Samir Ounzain reveals how his obsession with the…